Tratamiento de la osteoporosis

Nogués, Xavier; Martinez-Laguna, Daniel.
Med. clín (Ed. impr.) ; 150(12): 479-486, jun. 2018. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-173651

Documentos relacionados

  1. Novel formulations of oral bisphosphonates in the treatment of osteoporosis.
  2. Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
  3. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
  4. Polypharmacy in Osteoporosis Treatment.
  5. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
  6. Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO).
  7. Use of drugs against osteoporosis in the Baltic countries during 2010-2014.
  8. Aminobisphosphonates: Reconsideration 25 years after their approval for the treatment of osteoporosis.
  9. Treatment of osteoporosis after alendronate or risedronate.
  10. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.